Incidence, management, and outcome of lung cancer in patients with long-term oxygen therapy.
best supportive care
long-term oxygen therapy
lung cancer
stereotactic radiotherapy
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
09
2022
received:
21
07
2022
accepted:
29
09
2022
pubmed:
19
11
2022
medline:
5
1
2023
entrez:
18
11
2022
Statut:
ppublish
Résumé
Here, we aimed to assess the specific features of lung cancer in patients with long-term oxygen therapy (LTOT), and compare their outcomes with patients suffering from lung cancer without LTOT. This retrospective, case-controlled study included patients with LTOT and an incident diagnosis of lung cancer treated at Rouen University Hospital. Out of 2201 patients with LTOT, 31 were diagnosed with lung cancer. Among 24 patients with proven lung cancer, the most frequent histological type was squamous cell carcinoma (n = 12/24, 50%). Active treatment of any type was given in 19/31 (61%) and 41/62 (66%) of patients in the LTOT and control groups, respectively (p = 0.83). In the LTOT group, median survival was 38 days with best supportive care and 462 days with active treatment (p = 0.003). However, when adjusting on performance status and disease stage, LTOT was not significantly associated with a worse outcome. Hazard ratio (HR): 1.56 (95% confidence interval [CI]: 0.87 to 2.81) (p = 0.137). Administration of any treatment was associated with a better prognostic: HR: 0.35 (95% CI: 0.19 to 0.66). Both groups had a similar treatment safety profile. Incidence of lung cancer in patients with LTOT was comparable to the general population. The proportion of LTOT patients who received active treatment was similar to controls, and overall survival did not differ from controls in a multivariate analysis. Although reaching a histological diagnosis may be challenging in LTOT patients, the efficacy and safety of the management strategies of lung cancer seem preserved.
Sections du résumé
BACKGROUND
Here, we aimed to assess the specific features of lung cancer in patients with long-term oxygen therapy (LTOT), and compare their outcomes with patients suffering from lung cancer without LTOT.
METHODS
This retrospective, case-controlled study included patients with LTOT and an incident diagnosis of lung cancer treated at Rouen University Hospital.
RESULTS
Out of 2201 patients with LTOT, 31 were diagnosed with lung cancer. Among 24 patients with proven lung cancer, the most frequent histological type was squamous cell carcinoma (n = 12/24, 50%). Active treatment of any type was given in 19/31 (61%) and 41/62 (66%) of patients in the LTOT and control groups, respectively (p = 0.83). In the LTOT group, median survival was 38 days with best supportive care and 462 days with active treatment (p = 0.003). However, when adjusting on performance status and disease stage, LTOT was not significantly associated with a worse outcome. Hazard ratio (HR): 1.56 (95% confidence interval [CI]: 0.87 to 2.81) (p = 0.137). Administration of any treatment was associated with a better prognostic: HR: 0.35 (95% CI: 0.19 to 0.66). Both groups had a similar treatment safety profile.
CONCLUSION
Incidence of lung cancer in patients with LTOT was comparable to the general population. The proportion of LTOT patients who received active treatment was similar to controls, and overall survival did not differ from controls in a multivariate analysis. Although reaching a histological diagnosis may be challenging in LTOT patients, the efficacy and safety of the management strategies of lung cancer seem preserved.
Identifiants
pubmed: 36398413
doi: 10.1111/1759-7714.14692
pmc: PMC9807435
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-43Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Intensive Care Med. 2003 Jan;29(1):126-9
pubmed: 12528033
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Eur Respir J. 2016 Apr;47(4):1283-6
pubmed: 26869676
Sleep Med. 2019 Nov;63:41-45
pubmed: 31605903
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1063-7
pubmed: 10988131
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441
pubmed: 29632061
Chest. 2007 Dec;132(6):1932-8
pubmed: 18079226
N Engl J Med. 2013 May 23;368(21):1980-91
pubmed: 23697514
BMC Pulm Med. 2021 Aug 6;21(1):257
pubmed: 34362335
Eur Respir J. 1998 Oct;12(4):780-4
pubmed: 9817145
Thorac Cancer. 2023 Jan;14(1):36-43
pubmed: 36398413
PLoS One. 2015 Oct 13;10(10):e0140437
pubmed: 26460792
Rev Mal Respir. 2014 May;31(5):421-9
pubmed: 24878158
Eur J Cardiothorac Surg. 2010 Jul;38(1):6-13
pubmed: 20226682
Lung Cancer. 2014 Apr;84(1):13-22
pubmed: 24524818
Eur J Cardiothorac Surg. 2005 Jun;27(6):1099-105
pubmed: 15896625
Lung Cancer. 2016 Dec;102:122-134
pubmed: 27987580
Thorax. 2020 Nov;75(11):965-973
pubmed: 32895315
J Bronchology Interv Pulmonol. 2017 Apr;24(2):98-103
pubmed: 28005831
Rev Mal Respir. 2012 Apr;29(4):545-56
pubmed: 22542412
Nat Rev Cancer. 2013 Apr;13(4):233-45
pubmed: 23467302
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
Oncol Res Treat. 2016;39(10):587-590
pubmed: 27710970
Mol Cancer. 2022 Jan 20;21(1):25
pubmed: 35057806
Chest. 2022 Apr;161(4):1092-1100
pubmed: 34838524
Respiration. 2018;96(5):446-454
pubmed: 30007983
J Radiat Res. 2016 Jan;57(1):62-7
pubmed: 26487713
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1149-56
pubmed: 21640513
Diagnostics (Basel). 2022 Jan 25;12(2):
pubmed: 35204388